PMCB — Pharmacyte Biotech Cashflow Statement
0.000.00%
- $49.03m
- $34.77m
- 48
- 59
- 26
- 40
Annual cashflow statement for Pharmacyte Biotech, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2021 April 30th | 2022 April 30th | 2023 April 30th | 2024 April 30th | 2025 April 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -3.55 | -4.24 | -4.32 | 0.334 | 30.7 |
Non-Cash Items | 0.366 | 0.113 | 0.819 | -2.78 | -35 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -0.146 | 0.009 | -0.297 | 0.299 | 1.36 |
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Cash from Operating Activities | -3.33 | -4.12 | -3.79 | -2.15 | -2.98 |
Other Investing Cash Flow Items | 0 | 0 | 0 | -5 | -7 |
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 0 | 0 | 0 | -5 | -7 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 4.64 | 87.3 | -13.6 | -10.7 | -25 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 1.31 | 83.2 | -17.4 | -17.9 | -35 |